公开(公告)号：US20180022805A1

公开(公告)日：2018-01-25

申请号：US15548871

申请日：2016-02-05

Applicant: Bridget S. WILSON ,  Stuart S. WINTER ,  Michael Frank ERASMUS ,  Michael HOROWITZ ,  STC.UNM

Inventor： Bridget S. Wilson ,  Stuart S. Winter ,  Michael Frank Erasmus ,  Michael Horowitz

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.

公开(公告)号：US10988533B2

公开(公告)日：2021-04-27

申请号：US15548871

申请日：2016-02-05

Applicant: STC.UNM ,  Bridget S. Wilson ,  Stuart S. Winter ,  Michael Frank Erasmus ,  Michael Horowitz

Inventor： Bridget S. Wilson ,  Stuart S. Winter ,  Michael Frank Erasmus ,  Michael Horowitz

IPC: A61K39/395 ,  C07K16/28 ,  A61P35/02

Abstract: This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.

公开(公告)号：US20170296652A1

公开(公告)日：2017-10-19

申请号：US15509605

申请日：2015-09-17

Applicant: STC.UNM

Inventor： Bridget S. Wilson ,  Diane Lidke ,  Lydia Tapia ,  Mark Schulyer ,  Avanika Mahajan

IPC: A61K39/35 ,  C07K14/435 ,  C07K14/415

CPC classification number: A61K39/35 ,  A61K2039/577 ,  C07K14/415 ,  C07K14/43509 ,  C07K14/4702

Abstract: This disclosure describes recombinant hypoallergens and methods of treating allergy that involve administering a recombinant hypoallergen to a subject. Generally, the recombinant hypoallergen includes at least one amino acid modification compared to a corresponding wildtype allergen. As a result, the recombinant hypoallergen binds to IgE that specifically binds to the allergen, but induces release of histamine from basophils to a degree less than the wildtype allergen.